BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34047746)

  • 1. A novel peptide targeting c-Met for hepatocellular carcinoma diagnosis.
    Tang Y; Xu H; Dai Y; Wang F; Huang W; Liu P; Gu Y
    J Mater Chem B; 2021 Jun; 9(22):4577-4586. PubMed ID: 34047746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AT1R-Specific Ligand Angiotensin II as a Novel SPECT Agent for Hepatocellular Carcinoma Diagnosis.
    Tu Y; Liu Z; Wang F; Liu P; Tao J; Li C; Han Z; Li Z; Ma Y; Gu Y
    ACS Sens; 2020 Dec; 5(12):4072-4080. PubMed ID: 33232127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-modal imaging probe for EpCAM overexpressed in breast cancer.
    Dai Y; Tang Y; Huang W; Zhao Y; Gao X; Gu Y
    Talanta; 2022 Dec; 250():123715. PubMed ID: 35868149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of SP94 Peptide as a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy.
    Li Y; Hu Y; Xiao J; Liu G; Li X; Zhao Y; Tan H; Shi H; Cheng D
    Sci Rep; 2016 Sep; 6():33511. PubMed ID: 27649935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors.
    Esfahani SA; Heidari P; Kim SA; Ogino S; Mahmood U
    Theranostics; 2016; 6(12):2028-2038. PubMed ID: 27698938
    [No Abstract]   [Full Text] [Related]  

  • 7. An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis.
    Zhang Q; Han Z; Tao J; Zhao M; Zhang W; Li P; Tang L; Gu Y
    Biomater Sci; 2018 Dec; 7(1):159-167. PubMed ID: 30417190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a SPECT Tracer to Image c-Met Expression in a Xenograft Model of Non-Small Cell Lung Cancer.
    Han Z; Xiao Y; Wang K; Yan J; Xiao Z; Fang F; Jin Z; Liu Y; Sun X; Shen B
    J Nucl Med; 2018 Nov; 59(11):1686-1691. PubMed ID: 29777004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
    Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
    PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
    Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
    Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinobufacini inhibits epithelial-mesenchymal transition of human hepatocellular carcinoma cells through c-Met/ERK signaling pathway.
    Qi F; Wang J; Zhao L; Cai P; Tang W; Wang Z
    Biosci Trends; 2018 Jul; 12(3):291-297. PubMed ID: 29794405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis.
    Rhee H; Kim HY; Choi JH; Woo HG; Yoo JE; Nahm JH; Choi JS; Park YN
    Cancer Res; 2018 Apr; 78(7):1619-1631. PubMed ID: 29363547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
    Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
    World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of
    Zheng J; Miao W; Huang C; Lin H
    Ann Nucl Med; 2017 Jul; 31(6):486-494. PubMed ID: 28474165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe
    Shen JM; Li XX; Fan LL; Zhou X; Han JM; Jia MK; Wu LF; Zhang XX; Chen J
    Int J Nanomedicine; 2017; 12():1183-1200. PubMed ID: 28243083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary application of micro-SPECT/CT imaging by
    Zhang Y; Meng L; Li B; Tan H; Lin QY; Cheng D; Shi H
    Chem Biol Drug Des; 2019 Apr; 93(4):447-453. PubMed ID: 30381892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Met/MAPK pathway promotes the malignant progression of residual hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Jia G; Li F; Tong R; Liu Y; Zuo M; Ma L; Ji X
    Med Oncol; 2020 Nov; 37(12):117. PubMed ID: 33215351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
    Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
    Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.